

# Spinal Disorders - Dissemination of research findings to transform your practice and improve outcomes

**Breno Nery**

Neurosurgeon Beneficencia Portuguesa Hospital, Brazil

Spinal implants are used to treat spinal deformities such as isthmic spondylolisthesis and spinal stenosis. Spinal stenosis is usually a common problem in men and women over 50 years of age. With the increasing age, structural changes occur to the spine which incorporates joint issues, slip disk, and increasing stiffness of the tissue supporting the spine. This leads to the development of spinal deformities or impairment.

The occurrence rising and development of safer technology with cost-effective spinal devices, prevalence of spinal ailments and increasing demand for minimally invasive spine surgery are driving the expansion of the spinal implants market. Conversely, factors such as high procedural costs, stringent regulatory guidelines for the approval of new medical devices, and lack of reimbursements in developing countries are hampering the growth of the global spinal implants market.

Global spine biologics market generated revenue of \$1,644 million in 2015 and is projected to reach \$2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. Increase in the geriatric population with the various advantages of biologics like minimal faster recovery, postoperative time and their ability to activate cellular growth are the factors that drive the market growth. However, unfavorable reimbursement scenario, higher cost of the bone grafts, and certain ethical issues related to bone grafting procedures are expected to restrain the growth of the market.

Biologics are used during fusion procedure, as they stimulate bone growth formation through the inflammatory stage, repair stage, and remodelling stage. Therefore, the increase within the number of fusion surgery boosts the utilization of biologics.

For instance, Spinal Disorders such as spinal stenosis is the most common problem in men and women over 50 years. Aging leads to structural alterations in spine such as thickening of the band of the tissue that supports the spine and enlargement of bones & joints, thus resulting in spinal impairment. According to “Eurostat”, the population of the European Union (EU) was estimated to be 508.5 million on January 1, 2018. Aged population (65 or over) had a share of 18.9%, which showed an increase of 0.4% compared to the previous year. Therefore, older people who are at a higher risk to develop spinal deformities have increased chances to undergo spinal fusion surgery, which in turn is projected to increase the demand for spine biologics.

## Key Findings of the Spine Biologics Market:

The demineralized bone matrix segment is predicted to grow at a CAGR of three .4%, due to its ability to stimulate bone formation. Synthetic bone grafts segment accounted for more than half of the global bone graft substitutes market in 2018.

North America contributed a two-thirds share of the worldwide spine biologics market in 2018.

France and Germany jointly accounted for quite one-third share of the spine biologics market in 2018.

Japan is the major shareholder in the Asia-Pacific spine biologics market, accounting for more than one-third share in 2018.